JKJae Hoon Kim

Jae Hoon Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jae Hoon Kim has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Min Han

    Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea

    2 shared publications
  • Su Jin Jeong

    Division of Infectious Diseases, Department of Internal Medicine and AIDS Research Institute, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea

    2 shared publications
  • Ala Woo

    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

    1 shared publication
  • Ha Eun Kim

    Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul 03722, Republic of Korea

    1 shared publication
  • Hyukmin Lee

    Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea

    1 shared publication
  • Jaeeun Seong

    Division of Infectious Diseases, Seoul Medical Center, Seoul 02053, Republic of Korea

    1 shared publication

Latest Publications

  • Open Access

    Risk Factors for Mortality in Candida auris Bloodstream Infection: A Multicenter Study in South Korea, 2018–2025

    by Min Han, Jin Young Ahn, Jae Eun Seong, Se Ju Lee, Jinnam Kim, Jae Hoon Kim, Joon Sup Yeom, Jun Yong Choi, Su Jin Jeong, Jung Ho Kim, et al.

    Candida auris (C. auris) is a multidrug-resistant pathogen that spreads clonally in healthcare settings and was designated an urgent threat by the Centers for Disease Control and Prevention in 2019. We conducted a multicenter study to identify mortality risk factors in C. auris bloodstream infection (BSI) in South Korea. In this retrospective cohort study across three tertiary centers, 50 adults with first-episode C. auris BSI were analyzed. Primary and secondary outcomes were 30- and 90-day mortality. 30-day mortality was 24%, and 90-day mortality was 46%. Older age and higher Sequential Organ Failure Assessment score were independently associated with 30-day mortality. Microbiologic clearance within 30 days was protective. For 90-day mortality, older age was the only independent risk factor, and microbiologic clearance within 90 days was also protective. In conclusion, C. auris BSI causes substantial 30-day mortality, underscoring the need for risk-stratified, clearance-focused management.

  • Open Access

    Clinical Characteristics, Outcomes, and Distribution Patterns of Pathogens Causing Respiratory Infections in Lung Retransplant Recipients

    by Min Han, Jae Hoon Kim, Ala Woo, Song Yee Kim, Young Ho Yang, Ha Eun Kim, Jin Gu Lee, Moo Suk Park, Su Jin Jeong

    Introduction: With advances in surgical techniques and immunosuppressive therapies, lung retransplantation has become a viable option for patients experiencing graft failure. However, retransplantation is associated with inferior clinical outcomes, and infection remains a leading cause of morbidity and mortality in lung retransplant recipients. Objectives: This study examined clinical characteristics, outcomes, and microbial spectra of respiratory infections in lung retransplant recipients. Methods: This retrospective case–control study, conducted at two tertiary care centers, included 10 lung retransplant patients and 20 matched primary lung transplant patients. Respiratory pathogens identified using bronchoalveolar lavage (BAL) were compared between two groups over a two-year post-transplantation period. Results: Pulmonary hypertension was more prevalent in the retransplant group (p = 0.030). Five-year mortality and infection-related mortality were higher in the retransplant group (both p = 0.015), along with longer hospital and intensive care unit stays (p = 0.035 and 0.017, respectively). BAL cultures revealed distinct temporal patterns: Elizabethkingia predominated early (31.6% within 1 month) in the retransplant group, with Pseudomonas increasing gradually. The primary transplant group demonstrated a more heterogeneous distribution, with Acinetobacter, Pseudomonas, and Enterococcus detected early. Conclusions: Retransplant recipients exhibited worse clinical outcomes and a distinct temporal distribution of respiratory pathogens. Particularly, the high incidence of Elizabethkingia in lung retransplant recipients highlights the need for center-specific infection surveillance and tailored preventive strategies to improve retransplantation outcomes.